[ad_1]
[Reuters]— Johnson & Johnson (J & J), a major U.S. pharmaceutical and essentials company, announced on the 29th that the new coronavirus vaccine in development was 66% effective. We will apply for emergency use to the US Food and Drug Administration (FDA) next week, as well as other countries and the European Union (EU) soon.
About 44,000 people participated in large-scale clinical trials (clinical trials) conducted around the world. Efficacy for new moderate to severe crowns was 72% in the United States, 66% in Latin America, and 57% in South Africa. The spread of the mutant may have made a difference in efficacy. However, infectious disease and public health experts say it is enough to control the spread of infection and reduce mortality.
The efficacy of the approved vaccines manufactured by Pfizer Germany and Biontech Germany and Moderna USA is as high as about 95% with two vaccines, but clinical trials were conducted primarily in the United States and were the results before the mutant was detected .
The main goal of J&J vaccines is to prevent moderate to severe new crowns. Twenty-eight days after vaccination, the efficacy for the aggravation and hospitalization associated with the mutant infection was 85% in all regions. J&J Chief Scientific Officer Paul Stofels said the results “prevent the worsening and death of many corona patients.”
J&J has announced that it will produce in the United States, Europe, South Africa and India with a goal of supplying 1 billion doses in 2021. It said it was ready to ship as soon as emergency use was approved. However, Mr. Stoffels did not disclose the specific amount.
Regarding South African mutants, some studies have shown that the efficacy of the vaccine is reduced because it mutates in the target area of the vaccine, and Novabax Inc. announced the day before that the vaccine developed by the company is effective against South African mutants. . Sex was said to be low.
“It has become clear that the efficacy of the vaccine varies around the world,” Stoffels of J&J told Reuters. In a related clinical trial conducted in South Africa with 6,000 people, there was an 89% chance that severity could be prevented. Of the number of infections managed in this trial, 95% were from South African mutants.
J&J shares fell about 5% on the US stock market in the afternoon. Market officials say the vaccine is sold because it is inferior to other companies. However, Walid Gerad, associate professor of public health policy at the University of Pittsburgh, said: “The important thing is to prevent aggravation, hospitalization and death, not overall efficacy.”
J&J is conducting clinical trials in 8 countries. 44% of the participants were in the United States, 41% in Latin America and 15% in South Africa. By age, more than 30% were over 60 years old.
Unlike the Pfizer and Moderna vaccines, which require two doses, the J&J vaccine requires only one dose and does not require freezing, so it is effective in some areas where transport and freezing are a problem and is made into a vaccine.
